Abeona Therapeutics Inc vs Honest Company Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Honest Company Inc trades at $5.03 (market cap $558.95M). The key difference: Honest Company Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Honest Company Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | HNST | |
|---|---|---|
Market Cap | $421.19M | $558.95M |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $5.46 |
52-Week Low | $4.17 | $2.10 |
Enterprise Value | $276.10M | $462.56M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
HNST trades at $5.065, down 3.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue due to strategic exits. Despite negative net income margins and ROE, cash flow improved significantly in 2025 with $14.15M net cash flow. Analyst consensus shows 30% buy ratings amid ongoing profitability challenges.
The outlook remains cautious as strategic exits pressure revenue while cost improvements support margins. Investment opportunity exists if profitability targets are met, but risks include persistent net losses and competitive pressures in personal care markets. The stock's elevated P/E ratio of 48.83 requires careful valuation assessment.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →